The Japan Times - Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms

EUR -
AED 4.026896
AFN 70.723159
ALL 90.1587
AMD 392.449653
ANG 1.963177
AOA 1006.588011
ARS 1702.019352
AUD 1.628764
AWG 1.973701
AZN 1.862567
BAM 1.950553
BBD 2.207751
BDT 136.911698
BGN 1.944611
BHD 0.413586
BIF 3296.217924
BMD 1.0965
BND 1.412693
BOB 12.786603
BRL 6.358384
BSD 1.096166
BTN 102.401599
BWP 15.343794
BYN 3.289626
BYR 21491.406687
BZD 2.204659
CAD 1.568472
CDF 2515.371918
CHF 0.923971
CLF 0.027786
CLP 1094.065972
CNY 7.309436
CNH 7.310036
COP 3628.341559
CRC 488.284256
CUC 1.0965
CUP 26.308229
CVE 109.970676
CZK 24.395653
DJF 195.203998
DKK 7.474382
DOP 66.381128
DZD 150.418028
EGP 59.012221
ERN 16.447505
ETB 179.913419
FJD 2.519649
FKP 0.829592
GBP 0.832896
GEL 2.840082
GGP 0.829592
GHS 12.862987
GIP 0.829592
GMD 81.141062
GNF 9711.830245
GTQ 8.377578
GYD 229.22605
HKD 8.603416
HNL 29.470588
HRK 7.491252
HTG 143.61171
HUF 368.217972
IDR 20007.841726
ILS 3.575523
IMP 0.829592
INR 102.395095
IQD 1661.814453
IRR 2115207.823945
ISK 136.996884
JEP 0.829592
JMD 174.190621
JOD 0.777451
JPY 174.73446
KES 142.544481
KGS 95.888296
KHR 4471.909092
KMF 491.231894
KPW 986.850691
KRW 1460.384862
KWD 0.341757
KYD 0.913534
KZT 486.67637
LAK 24688.586062
LBP 98164.768386
LKR 364.748801
LRD 184.152937
LSL 18.545097
LTL 3.237681
LVL 0.663262
LYD 7.083912
MAD 10.940569
MDL 20.071464
MGA 4986.540398
MKD 61.509118
MMK 2301.978742
MNT 3954.806279
MOP 8.859289
MRU 44.417312
MUR 52.566064
MVR 16.878594
MWK 1900.769469
MXN 20.312625
MYR 4.512315
MZN 70.063987
NAD 18.544844
NGN 1481.788572
NIO 40.341295
NOK 10.61557
NPR 163.843503
NZD 1.995006
OMR 0.421578
PAB 1.096151
PEN 3.743729
PGK 4.931666
PHP 69.802147
PKR 303.069469
PLN 4.411336
PYG 6829.596788
QAR 3.996005
RON 5.346427
RSD 117.634775
RUB 90.29394
RWF 1622.321053
SAR 4.123832
SBD 8.922269
SCR 15.187537
SDG 659.537949
SEK 11.13291
SGD 1.414069
SHP 0.830179
SLE 25.001654
SLL 22993.067923
SOS 626.412054
SRD 41.050817
STD 22695.343237
STN 24.433937
SVC 9.591112
SYP 14256.697806
SZL 18.543202
THB 37.240494
TJS 10.101181
TMT 3.837751
TND 3.317122
TOP 2.64011
TRY 55.310329
TTD 7.421967
TWD 36.124751
TZS 2908.448548
UAH 49.691573
UGX 4548.618723
USD 1.0965
UYU 44.530008
UZS 13173.562242
VES 1003.848145
VND 28171.835016
VUV 132.747458
WST 3.095728
XAF 655.957
XAG 0.023963
XAU 0.000290787577
XCD 2.963347
XCG 1.975568
XDR 0.775283
XOF 655.957
XPF 119.331742
YER 259.377288
ZAR 18.828281
ZMK 9869.783261
ZMW 22.455491
ZWL 353.072662
SSP 6500.829822
MXV 2.278166
  • RYCEF

    0.1000

    19.81

    +0.5%

  • VOD

    -0.2500

    16.33

    -1.53%

  • CMSC

    -0.2800

    20.12

    -1.39%

  • RBGPF

    -2.0000

    65

    -3.08%

  • RIO

    -0.2500

    94.16

    -0.27%

  • BTI

    -1.2000

    54.85

    -2.19%

  • NGG

    -0.3000

    74.94

    -0.4%

  • GSK

    -0.3500

    49.35

    -0.71%

  • BCE

    -0.4200

    20.14

    -2.09%

  • CMSD

    -0.3400

    19.93

    -1.71%

  • BP

    -0.9100

    43.52

    -2.09%

  • RELX

    0.1700

    33.24

    +0.51%

  • BCC

    -0.6200

    75.97

    -0.82%

  • AZN

    -1.9400

    164.21

    -1.18%

  • JRI

    0.0000

    10.77

    0%

Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms
Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms

Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms

Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC ("Nutrecon"), and Gentle Technologies Corp ("Gentle Tech", and together with Bioceres Group and Nutrecon, the "Contributed Entities"), resulting in an enlarged corporate structure with Moolec as the parent company. In exchange, Moolec will issue a combination of up to 87 million newly issued shares and 5 million warrants to the shareholders of the Contributed Entities, as more fully described below in the Timing and Approvals section.

Text size:

LUXEMBOURG, LU / ACCESS Newswire / April 21, 2025 / Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination").

Federico Trucco, Bioceres Group's board member and CEO of Bioceres Crop Solutions Corp commented: "The need to accelerate agricultural innovation to address current and future challenges, such as enhancing on-farm profitability and reducing environmental impact, is increasingly evident. Molecular farming, as exemplified by Moolec Science, offers a compelling solution to the challenge of balancing productivity and sustainability. For instance, what soybean yield technology can rival the direct production of 300kg of animal protein from a 3-ton-per-hectare crop?" He then finished: "Moolec's recent transformational transaction represents the kind of bold action needed to drive radical change in agriculture. Integrating technologies and capabilities, along with a holistic perspective on agricultural evolution, are essential for moving beyond incremental improvements. Scale and visibility, both of which are key aspects of this transaction, are crucial to achieving this goal. Bioceres is enthusiastic to be part of a larger, more ambitious Moolec, one that expands its focus from science in food ingredients to a comprehensive 'cradle-to-cradle' approach."

Juan Sartori, Founder and Chairman of Union Group remarked: "This is not just a strategic alignment of businesses, it's the creation of a new kind of company for the 21st century. By combining science, scale, and sustainability, Moolec is positioned to lead a global transformation in how we produce food, materials, and energy. I'm proud to support this vision and the exceptional teams bringing it to life."

Following the closing of the Business Combination, Moolec will become uniquely positioned in the agricultural value-chain, with a powerful and validated technology discovery and development engine that can address in a cost-competitive way multiple upstream and downstream needs. Moolec's new value proposition will be centered around modifying or improving seeds and microbes to positively impact the way we utilize land and water resources, while preserving and/or improving human health.

Alejandro Antalich, Chairman of Synbio Powerlabs® added: "This combination marks a defining moment for the bioeconomy. By integrating next-gen ingredients, biological ag solutions, and deep-tech manufacturing capabilities under one roof, we are building a company with unmatched scientific depth and commercial reach. Together, we aim to accelerate the shift toward a more sustainable and resilient food system, one that works in harmony with nature, rather than against it."

As stated in their most recent annual reports, the companies and brands, which will be controlled or co-controlled by Moolec at the closing of the Business Combination, manage a portfolio of more than 800 patents (or patent applications) and over 550 product registrations, which translates into more than half a billion dollars of goods and services sold in their last fiscal year, to customers in more than 50 different countries.

José López Lecube, CFO and Director of Moolec commented: "This transformative transaction marks a new stage for Moolec, positioning the company for growth within a broader organization that facilitates synergies on multiple levels. Becoming part of a larger organization will enable cost efficiencies and significant revenue increase as well as product portfolio diversification. It will also enlarge our investor base, providing the company with new stakeholders who support Moolec's new and more diversified business."

Finally, as reported Mr. Gastón Paladini will step down as Chief Executive Officer (CEO), Director and Chairman of the Board, effective immediately following Moolec's Extraordinary General Meeting ("EGM") to be held on April 22, 2025.

Key highlights:

  • Ingredient Innovation: Moolec will continue to develop its flagship molecular farming products such as Piggy Sooy™ and GLASO™, while integrating Mycofood™ under the Eternal® brand from Nutrecon.

  • Biological Ag Expansion: Through Bioceres Group, Moolec will now offer upstream technologies for regenerative agriculture, including biological inputs and climate-resilient seeds like Rizobacter®, ProFarm®, and the HB4® trait.

  • Advanced R&D and Services: Leveraging expanded infrastructure, Moolec will offer R&D, CDMO, and regulatory services under the Agrality® and Synbio Powerlabs® brands, which are controlled or co-controlled by Bioceres Group and Nutrecon, respectively.

  • Emerging Tech & Equipment: The Company will also expand its reach into emerging technologies for grain and biomass transformation, especially in the biomaterials space, as well as new concepts on farm equipment, integrating material science, electric mobility, and autonomy. These emerging opportunities are being pursued by Gentle Tech and Bioceres Group subsidiaries.

  • Operational Synergies: The Business Combination is expected to result in significant cost synergies and an integrated management structure, which will be presented at or prior to closing of the Business Combination.

Timing and Approvals

The Business Combination was unanimously approved by the Board of Directors of all the entities participating in the deal. It is expected to close during the second quarter of 2025 or thereafter, and it is subject to finalizing Moolec's reverse stock split process and re-domicile to the Cayman Islands among other customary closing conditions and regulatory approvals. This includes the approval by Moolec's shareholders at a special meeting of shareholders of proposals relating to the Business Combination. Given that the transaction was originally proposed by about 70% of Moolec's current shareholders, the Company expects strong shareholder support for the Business Combination approval.

The Business Combination will be consummated through an equity exchange. Bioceres Group's shareholders will surrender their share ownership in Bioceres Group and will receive in exchange up to 80,590,280 shares of Moolec. The shareholders of 100% of Nutrecon and 50% of Gentle Tech will surrender their ownership in these two entities and will receive in exchange 6,475,000 shares of Moolec and 5,000,000 warrants of Moolec at a strike price of $2.00 per warrant, subject to adjustment based on the results of the reverse stock split process.

The intrinsic value of the exchange ratio and the $2 strike price of warrants represent both a compelling premium to Moolec's current stock price, and a unique opportunity to assemble one of the most formidable public companies in the agricultural industry.

Description of Contributed Entities and Assets

The Contributed Entities consist of Bioceres Group and its subsidiaries, Nutrecon and its subsidiaries and Gentle Tech and its subsidiaries.

Bioceres Group

  • Bioceres Crop Solutions Corp. (NASDAQ: BIOX)

    • Fully integrated provider of crop productivity solutions, including patented technologies for seeds and microbial agricultural inputs, as well as next generation crop nutrition and protection solutions. The company developed HB4® technology, which confers tolerance to climate changes in soybeans and wheat by allowing these crops to tolerate drought and soil salinity conditions. It also owns and licenses more than 570 products with approximately 750 patents and patent applications in the United States, Canada, Brazil, Argentina and other countries.

  • Bioceres Tech Services (Agrality® & Inmet)

    • Agrality® is a global agricultural services provider catering to agro-industrial companies worldwide. Their comprehensive service offerings encompass seed manufacturing and R&D, field-testing, and regulatory capabilities, ensuring their clients receive end-to-end solutions. Agrality's key assets include advanced seed production facilities, enabling high-quality seed development and production.

    • Inmet specializes in the bio-transformation of agro-industrial residues, offering sustainable solutions for waste management in the agricultural sector. They utilize innovative technologies to convert agricultural waste into valuable products. Additionally, Inmet is involved in the production and assessment of bioplastics, contributing to the development of eco-friendly alternatives to conventional plastics.

Nutrecon (Synbio Powerlabs®)

  • Headquartered in Helsinki, Finland, Synbio Powerlabs® is an innovative early-stage biotechnology company specialized in research, development, and production of sustainable fungi-derived ingredients. With state-of-the-art laboratories and a pilot-to-industrial scale precision fermentation facility, the company operates uniquely as both a Research and Technology Organization ("RTO") and a Contract Development and Manufacturing Organization ("CDMO"). This dual role enables Synbio Powerlabs® to seamlessly bridge the gap between cutting-edge biotechnology research and real-world industrial applications, accelerating the commercialization of novel bio-based products. Its flagship product line, marketed under the Eternal® brand, features a diverse portfolio of high-quality, sustainable ingredients derived from fungi, serving multiple industries and applications.

Gentle Tech (G-FAS & Gentle Farming)

  • A frontier tech company developing sustainable, autonomous agricultural equipment. Focused on reducing environmental impact through innovations in materials science, information technologies, and alternative energy to maximize efficiency and minimize the carbon footprint. The business model includes G-FAS (selling ultra-light weight harvesting heads directly to farmers) and Gentle Farming (developing machinery for autonomy and intelligent management).

Forward Looking Statements

This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

Contact Information

Press & Media: [email protected]
Investor Relations: [email protected]

SOURCE: Moolec Science SA



View the original press release on ACCESS Newswire

K.Yamaguchi--JT